Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577537 | 0.90 | MT-CO2 (0.43) | MT-CO2MEN1RAB9AKMT2APRKAA2 | |
| SCHEMBL5577502 | 0.88 | KDM4E (0.41) | MEN1KMT2AHTR4CHRM3KDM4E | |
| SCHEMBL5577723 | 0.86 | MT-CO2 (0.46) | MT-CO2MEN1RAB9AKMT2APRKAA2 | |
| SCHEMBL5577558 | 0.84 | MT-CO2 (0.47) | MT-CO2PRKAA2 | |
| SCHEMBL5577543 | 0.83 | MT-CO2 (0.44) | MT-CO2MEN1RAB9AKMT2APRKAA2 | |
| SCHEMBL5577431 | 0.83 | MT-CO2 (0.46) | MT-CO2PRKAA2P2RX7HTR4SIGMAR1 | |
| SCHEMBL5577623 | 0.82 | MT-CO2 (0.47) | MT-CO2MEN1RAB9AKMT2APRKAA2 | |
| SCHEMBL5577831 | 0.82 | DRD2 (0.45) | MEN1KMT2APRKAA2OPRL1DRD2 | |
| SCHEMBL5577874 | 0.82 | MT-CO2 (0.44) | MT-CO2PRKAA2KDM4EMAPT | |
| SCHEMBL5577587 | 0.81 | MT-CO2 (0.45) | MT-CO2MEN1RAB9AKMT2APRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885MEN1 748/4885RAB9A 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.